Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PPID | Q08752 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7446250 | 0.91 | NPSR1 (0.60) | MEN1KMT2ANPSR1SMN1; SMN2ADORA3 | |
| Methylene Chloride SCHEMBL28217271 | 0.90 | NPSR1 (0.57) | MEN1KMT2ANPSR1SMN1; SMN2ADORA3 | |
| SCHEMBL28858391 | 0.82 | ADORA3 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2ADORA3 | |
| SCHEMBL28514782 | 0.81 | NPSR1 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2ADORA3 | |
| SCHEMBL9853045 | 0.81 | MEN1 (0.56) | MEN1KMT2ATDP1SLC6A9SLC6A5 | |
| SCHEMBL25297216 | 0.78 | APAF1 (0.53) | MEN1KMT2ANPSR1SMN1; SMN2ADORA3 | |
| SCHEMBL25831273 | 0.78 | APAF1 (0.53) | MEN1KMT2ANPSR1SMN1; SMN2ADORA3 | |
| SCHEMBL9358683 | 0.77 | NPSR1 (0.45) | MEN1KMT2ANPSR1SMN1; SMN2ADORA3 | |
| SCHEMBL4679533 | 0.77 | KMT2A (0.55) | MEN1KMT2ASMN1; SMN2TDP1LMNA | |
| SCHEMBL7111411 | 0.77 | TOP2A (0.55) | NPSR1SMN1; SMN2LMNAKDM4EMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104677-B1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-12-07 | — | — | EP | disclosed |
| EP-2104677-B1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-12-07 | — | — | EP | disclosed |
| EP-2104677-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| US-7498339-B2 | Spiropiperidine glycinamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498339-B2 | Spiropiperidine glycinamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498339-B2 | Spiropiperidine glycinamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | US | disclosed |
| WO-2008084005-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084005-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | AVPR1A, AVPR1B, GLRA1 | MEN1 1334/4885KMT2A 1480/4885NPSR1 23/4885 |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | AVPR1A, AVPR2, AVPR1B | MEN1 1780/4885KMT2A 2040/4885NPSR1 12/4885 |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | AVPR1A, AVPR1B, GLRA1 | MEN1 1334/4885KMT2A 1480/4885NPSR1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.